Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report) CFO Terrance Coyne sold 232,536 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total transaction of $16,014,754.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Royalty Pharma Stock Performance
Shares of Royalty Pharma stock opened at $67.72 on Friday. Royalty Pharma PLC has a 52 week low of $37.31 and a 52 week high of $70.37. The stock has a market capitalization of $38.84 billion, a price-to-earnings ratio of 56.43, a PEG ratio of 1.36 and a beta of 0.37. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.29 and a current ratio of 1.29. The firm has a fifty day moving average of $62.11 and a two-hundred day moving average of $55.08.
Royalty Pharma Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. Royalty Pharma’s dividend payout ratio is 78.33%.
Institutional Trading of Royalty Pharma
Analyst Ratings Changes
Several equities research analysts have issued reports on RPRX shares. TD Cowen lifted their target price on shares of Royalty Pharma from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 14th. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Finally, Zacks Research raised Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus price target of $65.00.
View Our Latest Analysis on RPRX
About Royalty Pharma
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Articles
- Five stocks we like better than Royalty Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
